Skip to main content
Top
Published in: Japanese Journal of Radiology 2/2019

01-02-2019 | Prostate Cancer | Original Article

Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men

Authors: Ayumu Kido, Tsutomu Tamada, Naoki Kanomata, Akira Yamamoto, Yoshiyuki Miyaji, Atsushi Nagai, Teruki Sone

Published in: Japanese Journal of Radiology | Issue 2/2019

Login to get access

Abstract

Purpose

To clarify clinicopathological features of false-negative clinically significant prostate cancer (csPC) at multiparametric prostate MRI (mpMRI).

Methods

95 patients with 139 csPC undergoing 3T mpMRI before radical prostatectomy were included. Two radiologists were independently evaluated mpMR images using PI-RADS v2. Clinicopathological findings were compared between (a) detectable and undetectable lesions using overall mpMRI criteria (o-mpMRI criteria) and (b) lesions with early enhancement effect (EEE) and lesions without EEE at DCE-MRI.

Results

The detection rate of csPS using cutoff value of category 3 or more in PI-RADS v2 for positive lesion was 72.1% (98/136 lesions). In 38 false-negative lesions with less than PI-RADS v2 category 3, the DCE-MRI detected 14 lesions. 17 undetectable lesions on o-mpMR criteria had lower PSA and D’amico risk classification, and higher tumor apparent diffusion coefficient (ADC) than those of 118 detectable lesions (p ≤ 0.048). 89 lesions with EEE showed higher PSA, tumor size, prostatectomy GS grade, frequency of lesions with GS ≥ 4 + 3 and lower tumor ADC than those in 38 lesions without EEE (p ≤ 0.046).

Conclusion

Tumor detectability of csPC with PI-RADS v2 was limited compared with o-mpMRI criteria in Japanese men. Moreover, false-negative lesions on o-mpMRI criteria were characterized as small in size, low risk and low cellularity.
Literature
3.
go back to reference Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging—reporting and data system: 2015, Version 2. Eur Urol. 2016;69:16–40.CrossRefPubMed Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging—reporting and data system: 2015, Version 2. Eur Urol. 2016;69:16–40.CrossRefPubMed
4.
go back to reference Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016;71:618–29.CrossRefPubMed Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016;71:618–29.CrossRefPubMed
5.
go back to reference Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46–66.CrossRefPubMed Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46–66.CrossRefPubMed
6.
go back to reference Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.CrossRefPubMed Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.CrossRefPubMed
7.
go back to reference Auer T, Edlinger M, Bektic J, Nagele U, Herrmann T, Schäfer G, et al. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results. World J Urol. 2017;35:687–93.CrossRefPubMed Auer T, Edlinger M, Bektic J, Nagele U, Herrmann T, Schäfer G, et al. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results. World J Urol. 2017;35:687–93.CrossRefPubMed
8.
go back to reference Greer MD, Shih JH, Lay N, Barrett T, Kayat Bittencourt L, Borofsky S, et al. Validation of the dominant sequence paradigm and role of dynamic contrast-enhanced imaging in PI-RADS version 2. Radiology. 2017;285:859–69.CrossRefPubMed Greer MD, Shih JH, Lay N, Barrett T, Kayat Bittencourt L, Borofsky S, et al. Validation of the dominant sequence paradigm and role of dynamic contrast-enhanced imaging in PI-RADS version 2. Radiology. 2017;285:859–69.CrossRefPubMed
9.
go back to reference Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology. 2018;286:186–95.CrossRefPubMed Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology. 2018;286:186–95.CrossRefPubMed
10.
go back to reference Seo JW, Shin SJ, Taik OhY, Jung DC, Cho NH, Choi YD, et al. PI-RADS version 2: detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer. AJR Am J Roentgenol. 2017;209:W1–9.CrossRefPubMed Seo JW, Shin SJ, Taik OhY, Jung DC, Cho NH, Choi YD, et al. PI-RADS version 2: detection of clinically significant cancer in patients with biopsy gleason score 6 prostate cancer. AJR Am J Roentgenol. 2017;209:W1–9.CrossRefPubMed
11.
go back to reference Rosenkrantz AB, Babb JS, Taneja SS, Ream JM. Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology. 2017;283:119–29.CrossRefPubMed Rosenkrantz AB, Babb JS, Taneja SS, Ream JM. Proposed adjustments to PI-RADS version 2 decision rules: impact on prostate cancer detection. Radiology. 2017;283:119–29.CrossRefPubMed
12.
go back to reference Park SY, Jung DC, Oh YT, Cho NH, Choi YD, Rha KH, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology. 2016;280:108–16.CrossRefPubMed Park SY, Jung DC, Oh YT, Cho NH, Choi YD, Rha KH, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology. 2016;280:108–16.CrossRefPubMed
13.
go back to reference Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.CrossRefPubMed Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.CrossRefPubMed
14.
go back to reference de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202:343–51.CrossRefPubMed de Rooij M, Hamoen EH, Fütterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202:343–51.CrossRefPubMed
15.
go back to reference Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569–76.CrossRefPubMed Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015;67:569–76.CrossRefPubMed
16.
go back to reference Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. J Urol. 2012;187:2032–8.CrossRefPubMed Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS. Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. J Urol. 2012;187:2032–8.CrossRefPubMed
17.
go back to reference Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection–histopathologic correlation. Radiology. 2010;255:89–99.CrossRefPubMedPubMedCentral Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection–histopathologic correlation. Radiology. 2010;255:89–99.CrossRefPubMedPubMedCentral
18.
go back to reference Tan N, Margolis DJ, Lu DY, King KG, Huang J, Reiter RE, et al. Characteristics of detected and missed prostate cancer foci on 3-T multiparametric MRI using an endorectal coil correlated with whole-mount thin-section histopathology. AJR Am J Roentgenol. 2015;205:W87–92.CrossRefPubMedPubMedCentral Tan N, Margolis DJ, Lu DY, King KG, Huang J, Reiter RE, et al. Characteristics of detected and missed prostate cancer foci on 3-T multiparametric MRI using an endorectal coil correlated with whole-mount thin-section histopathology. AJR Am J Roentgenol. 2015;205:W87–92.CrossRefPubMedPubMedCentral
19.
go back to reference Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of gleason subtype on prostate cancer detection using multiparametric magnetic resonance imaging: correlation with final histopathology. J Urol. 2017;198:316–21.CrossRefPubMed Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of gleason subtype on prostate cancer detection using multiparametric magnetic resonance imaging: correlation with final histopathology. J Urol. 2017;198:316–21.CrossRefPubMed
20.
go back to reference Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, et al. A comprehensive analysis of cribriform morphology on magnetic resonance imaging/ultrasound fusion biopsy correlated with radical prostatectomy specimens. J Urol. 2018;199:106–13.CrossRefPubMed Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, et al. A comprehensive analysis of cribriform morphology on magnetic resonance imaging/ultrasound fusion biopsy correlated with radical prostatectomy specimens. J Urol. 2018;199:106–13.CrossRefPubMed
21.
go back to reference Ohori M, Kattan M, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. Mod Pathol. 2004;17:349–59.CrossRefPubMed Ohori M, Kattan M, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. Mod Pathol. 2004;17:349–59.CrossRefPubMed
22.
go back to reference Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–52.PubMed Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–52.PubMed
23.
go back to reference Tamada T, Sone T, Kanomata N, Miyaji Y, Kido A, Jo Y, et al. Value of preoperative 3T multiparametric MRI for surgical margin status in patients with prostate cancer. J Magn Reson Imaging. 2016;44:584–93.CrossRefPubMed Tamada T, Sone T, Kanomata N, Miyaji Y, Kido A, Jo Y, et al. Value of preoperative 3T multiparametric MRI for surgical margin status in patients with prostate cancer. J Magn Reson Imaging. 2016;44:584–93.CrossRefPubMed
24.
go back to reference Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol. 2011;197:664–70.CrossRefPubMed Tamada T, Sone T, Higashi H, Jo Y, Yamamoto A, Kanki A, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol. 2011;197:664–70.CrossRefPubMed
25.
go back to reference Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al. Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846–53.CrossRefPubMed Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al. Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846–53.CrossRefPubMed
26.
go back to reference Boesen L, Nørgaard N, Løgager V, Thomsen HS. Clinical outcome following low suspicion multiparametric prostate magnetic resonance imaging or benign magnetic resonance imaging guided biopsy to detect prostate cancer. J Urol. 2017;198:310–5.CrossRefPubMed Boesen L, Nørgaard N, Løgager V, Thomsen HS. Clinical outcome following low suspicion multiparametric prostate magnetic resonance imaging or benign magnetic resonance imaging guided biopsy to detect prostate cancer. J Urol. 2017;198:310–5.CrossRefPubMed
27.
go back to reference Cash H, Günzel K, Maxeiner A, Stephan C, Fischer T, Durmus T, et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int. 2016;118:35–43.CrossRefPubMed Cash H, Günzel K, Maxeiner A, Stephan C, Fischer T, Durmus T, et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int. 2016;118:35–43.CrossRefPubMed
28.
go back to reference Tamada T, Prabhu V, Li J, Babb JS, Taneja SS, Rosenkrantz AB. Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age. Abdom Radiol (NY). 2017;42:1744–51.CrossRef Tamada T, Prabhu V, Li J, Babb JS, Taneja SS, Rosenkrantz AB. Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age. Abdom Radiol (NY). 2017;42:1744–51.CrossRef
29.
go back to reference Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–400.CrossRefPubMed Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–400.CrossRefPubMed
30.
go back to reference Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161:152–5.CrossRefPubMed Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161:152–5.CrossRefPubMed
31.
go back to reference Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–7.CrossRefPubMed Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–7.CrossRefPubMed
32.
go back to reference Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, Kraus S, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int. 2009;103:883–8.CrossRefPubMed Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, Kraus S, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int. 2009;103:883–8.CrossRefPubMed
33.
go back to reference De Cobelli F, Ravelli S, Esposito A, Giganti F, Gallina A, Montorsi F, et al. Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR Am J Roentgenol. 2015;204:550–7.CrossRefPubMed De Cobelli F, Ravelli S, Esposito A, Giganti F, Gallina A, Montorsi F, et al. Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR Am J Roentgenol. 2015;204:550–7.CrossRefPubMed
34.
go back to reference Tamada T, Prabhu V, Li J, Babb JS, Taneja SS, Rosenkrantz AB. Prostate cancer: diffusion-weighted MR imaging for detection and assessment of aggressiveness-comparison between conventional and kurtosis models. Radiology. 2017;284:100–8.CrossRefPubMed Tamada T, Prabhu V, Li J, Babb JS, Taneja SS, Rosenkrantz AB. Prostate cancer: diffusion-weighted MR imaging for detection and assessment of aggressiveness-comparison between conventional and kurtosis models. Radiology. 2017;284:100–8.CrossRefPubMed
35.
go back to reference Tamada T, Dani H, Taneja SS, Rosenkrantz AB. The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. Abdom Radiol (NY). 2017;42:2340–5.CrossRef Tamada T, Dani H, Taneja SS, Rosenkrantz AB. The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. Abdom Radiol (NY). 2017;42:2340–5.CrossRef
36.
go back to reference Tamada T, Kanomata N, Sone T, Jo Y, Miyaji Y, Higashi H, et al. High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLoS One. 2014;9:e96619.CrossRefPubMedPubMedCentral Tamada T, Kanomata N, Sone T, Jo Y, Miyaji Y, Higashi H, et al. High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLoS One. 2014;9:e96619.CrossRefPubMedPubMedCentral
37.
go back to reference Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.CrossRefPubMed Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.CrossRefPubMed
38.
go back to reference Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672–7.CrossRefPubMed Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672–7.CrossRefPubMed
Metadata
Title
Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men
Authors
Ayumu Kido
Tsutomu Tamada
Naoki Kanomata
Akira Yamamoto
Yoshiyuki Miyaji
Atsushi Nagai
Teruki Sone
Publication date
01-02-2019
Publisher
Springer Japan
Published in
Japanese Journal of Radiology / Issue 2/2019
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-018-0801-9

Other articles of this Issue 2/2019

Japanese Journal of Radiology 2/2019 Go to the issue